EP2396334A1 - N-[(2-azabicyclo[2.1.1]hex-1-yl]arylmethyl] benzamidderivate, deren herstellung und deren therapeutische verwendung - Google Patents

N-[(2-azabicyclo[2.1.1]hex-1-yl]arylmethyl] benzamidderivate, deren herstellung und deren therapeutische verwendung

Info

Publication number
EP2396334A1
EP2396334A1 EP10708303A EP10708303A EP2396334A1 EP 2396334 A1 EP2396334 A1 EP 2396334A1 EP 10708303 A EP10708303 A EP 10708303A EP 10708303 A EP10708303 A EP 10708303A EP 2396334 A1 EP2396334 A1 EP 2396334A1
Authority
EP
European Patent Office
Prior art keywords
methyl
phenyl
hex
benzamide
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP10708303A
Other languages
English (en)
French (fr)
Inventor
Gihad Dargazanli
Geneviève ESTENNE-BOUHTOU
Abdel-Kader Mafroud
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi SA
Original Assignee
Sanofi SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi SA filed Critical Sanofi SA
Publication of EP2396334A1 publication Critical patent/EP2396334A1/de
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/52—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring condensed with a ring other than six-membered

Definitions

  • the present invention relates to ⁇ / - [(2-aza-bicyclo [2.2.1] hex-1-yl) -aryl-methyl] -benzamide derivatives, to their preparation and their therapeutic application in the treatment of or the prevention of diseases involving glycine carriers Glyti.
  • the diamine of general formula (II) can be prepared by processes illustrated by Schemes 2 for the amine (IIa) and 3 for the amine (Nb) and (IIc) which follow:
  • the compounds of the invention have been subjected to a series of pharmacological tests which have demonstrated their interest as substances with therapeutic activities. Study of the glycine transport in SK-N-MC cells expressing the native glyti human transporter.
  • compositions according to the invention can thus be intended for oral, sublingual, subcutaneous, intramuscular, intravenous, topical, intratracheal, intranasal, transdermal, rectal, intraocular administration.
  • the unit dosage forms may be, for example, tablets, capsules, granules, powders, oral or injectable solutions or suspensions, transdermal patches, suppositories.
  • topical administration we can consider ointments, lotions and eye drops.
  • the dose of active ingredient administered per day can reach 0.1 to 20 mg / kg, in one or more doses.
EP10708303A 2009-02-10 2010-02-09 N-[(2-azabicyclo[2.1.1]hex-1-yl]arylmethyl] benzamidderivate, deren herstellung und deren therapeutische verwendung Withdrawn EP2396334A1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0900578A FR2941953B1 (fr) 2009-02-10 2009-02-10 Derives de n-°(2-aza-bicyclo°2.1.1!hex-1-yl)-benzamide, leur preparation et leur application en therapeutique
PCT/FR2010/050203 WO2010092286A1 (fr) 2009-02-10 2010-02-09 Derives de n-[(2-aza-bicyclo[2.1.1]hex-1-yl]-aryl-methyl]-benzamide, leur preparation et leur application en therapeutique

Publications (1)

Publication Number Publication Date
EP2396334A1 true EP2396334A1 (de) 2011-12-21

Family

ID=40935627

Family Applications (1)

Application Number Title Priority Date Filing Date
EP10708303A Withdrawn EP2396334A1 (de) 2009-02-10 2010-02-09 N-[(2-azabicyclo[2.1.1]hex-1-yl]arylmethyl] benzamidderivate, deren herstellung und deren therapeutische verwendung

Country Status (17)

Country Link
US (1) US20120071536A1 (de)
EP (1) EP2396334A1 (de)
JP (1) JP2012517411A (de)
KR (1) KR20110118812A (de)
CN (1) CN102388049A (de)
AR (1) AR075379A1 (de)
AU (1) AU2010212702A1 (de)
BR (1) BRPI1008660A2 (de)
CA (1) CA2751863A1 (de)
FR (1) FR2941953B1 (de)
IL (1) IL214490A0 (de)
MX (1) MX2011008447A (de)
RU (1) RU2011137463A (de)
SG (1) SG173606A1 (de)
TW (1) TW201036979A (de)
UY (1) UY32428A (de)
WO (1) WO2010092286A1 (de)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2861070B1 (fr) * 2003-10-17 2006-01-06 Sanofi Synthelabo Derives de n-[phenyl(pyrrolidin-2-yl)methyl]benzamide et n-[(azepan-2-yl)phenylmethyl]benzamide, leur preparation et leur application en therapeutique
FR2861076B1 (fr) * 2003-10-17 2006-01-06 Sanofi Synthelabo Derives de n-heterocyclymethylbenzamide, leur preparation et leur application en therapeutique
WO2005058317A1 (en) * 2003-12-18 2005-06-30 Glaxo Group Limited Glycine transporter-1 inhibirors
WO2007053400A2 (en) * 2005-10-28 2007-05-10 Merck & Co., Inc. Piperidine glycine transporter inhibitors
TW200911808A (en) * 2007-07-23 2009-03-16 Astrazeneca Ab Novel compounds

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO2010092286A1 *

Also Published As

Publication number Publication date
US20120071536A1 (en) 2012-03-22
FR2941953B1 (fr) 2011-04-08
TW201036979A (en) 2010-10-16
CN102388049A (zh) 2012-03-21
UY32428A (es) 2010-09-30
IL214490A0 (en) 2011-09-27
BRPI1008660A2 (pt) 2016-03-08
KR20110118812A (ko) 2011-11-01
CA2751863A1 (fr) 2010-08-19
FR2941953A1 (fr) 2010-08-13
SG173606A1 (en) 2011-09-29
MX2011008447A (es) 2011-11-29
JP2012517411A (ja) 2012-08-02
AU2010212702A1 (en) 2011-09-01
WO2010092286A1 (fr) 2010-08-19
AR075379A1 (es) 2011-03-30
RU2011137463A (ru) 2013-03-20

Similar Documents

Publication Publication Date Title
EP1682503B1 (de) Derivate von n-[phenyl(alkylpiperidin-2-yl)methyl]benzamid, verfahren zu deren herstellung und deren anwendung in therapeutika
EP1499589B1 (de) N-¬phenyl(piperidin-2-yl)methyl|benzamidderivate,verfahren zu ihrer herstellung und ihre therapeutische anwendung
EP1527048B1 (de) N-[phenyl(piperidin-2-yl)methyl]benzamid-derivate, verfahren zu deren herstellung und ihre therapeutische verwendung
CA2542647C (fr) Derives de n-heterocyclylmethylbenzamides, leur preparation et leur application en therapeutique
EP1680400B1 (de) Derivate von n-[phenyl(pyrrolidin-2-yl)methyl]benzamid und n-[(azepan-2-yl)phenylmethyl]benzamid, verfahren zu deren herstellung und deren anwendung in therapeutika
FR2861074A1 (fr) Derives de n-[phenyl(piperidin-2-yl)methyl]benzamide, leur preparation et leur application en therapeutique
CA2542370A1 (fr) Derives de n-[heteroaryl(piperidin-2-yl)methyl]benzamide, leur preparation et leur application en therapeutique
WO2004013100A2 (fr) Derives de n-[phenyl(piperidin-2-yl)methyl]benzamide, leur preparation et leur application en therapeutique
EP2408778A1 (de) N-[(6-azabicyclo[3.2.1]oct-5-yl]arylmethyl] heterobenzamidderivate, deren herstellung und deren therapeutische verwendung
EP2077837A2 (de) Derivate von pyrrolizin, indolizin und chinolizin, ihre herstellung und ihre therapeutische verwendung
EP2396334A1 (de) N-[(2-azabicyclo[2.1.1]hex-1-yl]arylmethyl] benzamidderivate, deren herstellung und deren therapeutische verwendung
EP2419431A1 (de) Derivate von n-[(7-azabicyclo[2.2.1]hept-1-yl)arylmethyl] benzamid, dessen herstellung und dessen therapeutische verwendung
EP2408763A2 (de) N-[(2-aza-bicyclo[2.1.1]hex-1-yl)-aryl-methyl]-heterobenzamidderivate, ihre herstellung und anwendung für therapeutische zwecke
EP2396335A1 (de) N[(6-azabicyclo[3.2.1]oct-1-yl)arylmethyl] benzamidderivate, deren herstellung und deren therapeutische verwendung
FR2943056A1 (fr) Derives de n-°2-aza-bicyclo°2.1.1!hex-1-yl)-aryl-methyl!- heterobenzamide, leur preparation et leur application en therapeutique
FR2944283A1 (fr) Derives de n-°(2-aza-bicyclo°2.1.1!hex-1-yl)-aryl-methyl!- heterobenzamide, leur preparation et leur application en therapeutique

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20110912

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK SM TR

AX Request for extension of the european patent

Extension state: AL BA RS

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: SANOFI

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: SANOFI

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20120411